Sonoma Pharmaceuticals (SNOA) Cash from Financing Activities (2010 - 2026)
Sonoma Pharmaceuticals (SNOA) posted quarterly Cash from Financing Activities of $387000.0 for Q1 2026, up 59.92% year-over-year from $242000.0 in Q1 2025, and up 84.29% quarter-over-quarter from $210000.0 in Q4 2025.
Sonoma Pharmaceuticals (SNOA) Cash from Financing Activities (2010 - 2026) Analysis & Trends
Sonoma Pharmaceuticals' Cash from Financing Activities history runs 17 years deep, the most recent figure standing at $387000.0 for Q1 2026.
- In Q1 2026, Cash from Financing Activities rose 59.92% year-over-year to $387000.0; the TTM figure through Mar 2026 stood at $477000.0 (down 84.26% YoY), while the FY2026 annual figure was $477000.0, down 84.26% from the prior year.
- Cash from Financing Activities for Q1 2026 stood at $387000.0, up from $210000.0 in the prior quarter.
- The five-year high for Cash from Financing Activities was $3.4 million in Q1 2023, with the low at -$387000.0 in Q2 2022.
- The 5-year median for Cash from Financing Activities is $222000.0 (2022), against an average of $464352.9.
- The sharpest annual moves came in 2022 and 2023: Cash from Financing Activities sank 168.68% in 2022, then soared 1418.92% in 2023.
- Sonoma Pharmaceuticals' Cash from Financing Activities stood at -$318000.0 in 2022, then surged by 514.47% to $1.3 million in 2023, then tumbled by 46.28% to $708000.0 in 2024, then slumped by 70.34% to $210000.0 in 2025, then surged by 84.29% to $387000.0 in 2026.
- Business Quant data shows SNOA's Cash from Financing Activities at $387000.0 in Q1 2026, $210000.0 in Q4 2025, and -$62000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | -1.00 Mn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | -813.00 Mn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | -1.13 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 122.40 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | -1.24 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 63.40 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | -74.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Sonoma Pharmaceuticals | 5.17 Mn | -165,129.89 | 2.58 Mn | 3.45 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.45 Mn |
| Jun 30, 2026 | 3.45 Mn |
| Mar 31, 2026 | 387,000.00 |
| Mar 31, 2026 | 387,000.00 |
| Dec 31, 2025 | 210,000.00 |
| Dec 31, 2025 | 210,000.00 |
| Sep 30, 2025 | -62,000.00 |
| Sep 30, 2025 | -62,000.00 |
| Jun 30, 2025 | -58,000.00 |
| Jun 30, 2025 | -58,000.00 |
| Mar 31, 2025 | 242,000.00 |
| Mar 31, 2025 | 242,000.00 |
| Dec 31, 2024 | 708,000.00 |
| Dec 31, 2024 | 708,000.00 |
| Sep 30, 2024 | 1.44 Mn |
| Sep 30, 2024 | 1.44 Mn |
| Jun 30, 2024 | 636,000.00 |
| Jun 30, 2024 | 636,000.00 |
| Mar 31, 2024 | 622,000.00 |
| Mar 31, 2024 | 622,000.00 |